Tscan Therapeutics is trading at $0.24, up 5.96%, but the reason for the gain remains unclear. - No fresh company-specific announcement was identified for October 9, 2026; the latest press release listed by the company is dated September 2. - Biotech sector weakness is a conflicting backdrop, while broader index moves are modest; available evidence does not establish a cause. - Cited pre-market coverage also reported no clear company-specific catalyst.